Compare Amylx Pharmaceuticals Inc (AMLX) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Quest Diagnostics Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Quest Diagnostics Inc trades at $207.44 (market cap $22.96B). The key difference: Quest Diagnostics Inc is far larger — about 11.6× Amylx Pharmaceuticals Inc's market cap, and Quest Diagnostics Inc pays a 1.66% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DGX | |
|---|---|---|
Market Cap | $1.98B | $22.96B |
Sector | Health | Health |
52-Week High | $18.70 | $216.02 |
52-Week Low | $7.64 | $166.42 |
Enterprise Value | $1.70B | $28.98B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Quest Diagnostics (DGX) trades at $207.44, down 0.29% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported $11.04B revenue in 2025 with a 9.08% net margin, supported by strong cash flow from operations of $1.89B. Recent news highlights expansion of oncology testing services, including New York State approval for Haystack MRD, enhancing its diagnostic portfolio.
DGX offers steady growth with a consensus price target of $226, implying 9% upside. Risks include rising debt levels and healthcare policy uncertainties, but analyst sentiment leans positive with 38% buy ratings. The stock's valuation at a P/E of 22.92 appears reasonable given its profitability and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
